Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
All content for Talk Radioisotopes: Going Nuclear on Cancer is the property of Nusano and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
The Goldilocks Isotope? Why Astatine-211 Might Be Just Right for Radiotherapeutics
Talk Radioisotopes: Going Nuclear on Cancer
38 minutes 5 seconds
5 months ago
The Goldilocks Isotope? Why Astatine-211 Might Be Just Right for Radiotherapeutics
On this episode, Scott and Sarah are joined by Milton Lönnroth, Co-Founder and CEO of Atley Solutions
Talk Radioisotopes: Going Nuclear on Cancer
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
